AstraZeneca, Ionis report major trial failure with heart disease drug
AstraZeneca and Ionis share prices plunge following the failure of a key clinical trial for the heart disease drug Wainua.
Evidence dossier
Intelligence passport
Measured timeline
Sources (8)
-
Major drugmaker loses $27 billion in market value after failed trialMarketWatch · 102d ago
-
BBIO Stock Surges 16% As AstraZeneca-Ionis Heart Drug Trial Misses GoalStocktwits · 102d ago
-
AZ, Ionis shares tumble on ATTR-CM trial flop, but analyst flags over-reactionFierce Pharma · 102d ago
-
IONS Stock Heads Toward Biggest Single-Day Slump In Over 5 YearsYahoo Finance · 102d ago
-
AstraZeneca's Wainua fails key heart disease trial, shares tumbleReuters · 102d ago
-
-
-
The story so far
- Velocity & Diffusion: Coverage exploded across 8 distinct news outlets with 8 published articles, achieving a live velocity of 6.
- Primary Driver: AstraZeneca and Ionis share prices plunge following the failure of a key clinical trial for the heart disease drug Wainua.
- Predictive Outlook: Archynetys algorithmic models forecast this story will fade from trending status over the next 24 hours.
- Source Integrity: Verified strictly against primary headline reporting under zero-hallucination protocols.
AstraZeneca and Ionis have reported a major trial failure for their heart disease drug, Wainua. The news has led to a decline in share prices for both companies.
Coverage from Reuters, CNBC, and the Wall Street Journal emphasizes the market impact, noting that AstraZeneca stock dropped 9%. Yahoo Finance reports that Ionis (IONS) is heading toward its biggest single-day slump in over five years.
Further updates are expected as the companies address the trial miss, which CNBC described as a rare blow to the pharmaceutical powerhouse AstraZeneca.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 102d ago.
The obvious questions
Which drug failed the clinical trial?
The heart disease drug named Wainua.
How did AstraZeneca's stock react?
According to CNBC, AstraZeneca stock dropped 9%.
What is the impact on Ionis stock?
Yahoo Finance reports that IONS stock is heading toward its biggest single-day slump in over five years.
How fast it spread
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
How do you expect this trend to evolve over the next 24 hours?
Cast your vote to register reader intelligence on the velocity and trajectory of this coverage.
Topics
Related trends
Hypertension treatment could avert over 500,000 heart disease deaths
Hypertension treatment could save hundreds of thousands of lives.
Hooked to magnesium? Here’s why most don’t need it as a supplement
Most people don't need magnesium supplements, experts warn.
Merck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to make
Merck's cancer vaccine production timeline is expected to shorten.
Roche Licenses Obesity Therapy From China’s Rona in Up to $1.2 Billion Deal
Roche licenses obesity therapy from China's Rona in major deal
BMS doubles up with pivotal wins in lung disease, solid tumor that offer hope for post-patent cliff growth
8 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
AstraZeneca blames trial design for Phase 3 failure of bone disease drug
AstraZeneca's bone disease drug fails Phase 3 trial due to high placebo response.
Open prediction lab
Can you beat the machine?
Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.
📬 The daily trend digest
The world's top trends, once a day. No spam, one-click unsubscribe.